Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies

References

• Arbyn M, Ronco G, Anttila A, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–F99.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev. 2013;3:1–201.
   Google Scholar
• Zuna RE, Wang SS, Rosenthal DL, et al. Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS). Cancer. 2005;105:253–262.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Xu L, Verdoodt F, et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med. 2017;166:118–127.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Depuydt C, Benoy I, et al. VALGENT: a protocol for clinical validation of human papillomavirus assays. J Clin Virol. 2016;76(Suppl 1):S14–S21.
   PubMedGoogle Scholar
• Rebolj M, Lynge E, Bonde J. Human papillomavirus testing and genotyping in cervical screening. Expert Rev Anticancer Ther. 2011;11:1025–1033.
   Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958–966.
   PubMed Web of Science ®Google Scholar
• Poljak M, Kocjan BJ, Ostrbenk A, et al. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016;76(Suppl 1):S3–S9.
   PubMedGoogle Scholar
• Geraets D, Cuschieri K, Koning M, et al. Clinical evaluation of a GP5+/6+-based Luminex assay having full high-risk HPV genotyping capability and an internal control. J Clin Microbiol. 2014;52:3996–4002.
   PubMed Web of Science ®Google Scholar
• Geraets DT, Cuschieri K, de Koning MN, et al. Correction for Geraets et al., Clinical Evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol. 2016;54:1927.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Depuydt C, Benoy I, et al. Prevalence and viral load of 51 genital human papillomavirus types and 3 subtypes. Int J Cancer. 2013;132:2395–2403.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Depuydt C, Benoy I, et al. Multiple HPV infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol. 2013;51:1458–1464.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Depuydt CE, Benoy I, et al. Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions. Cancer Epidemiol Biomarkers Prev. 2013;22:406–414.
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Geraets DT, Moore C, et al. Clinical and analytical performance of the Onclarity HPV assay using the VALGENT framework. J Clin Microbiol. 2015;53:3272–3279.
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Geraets D, Cuzick J, et al. Performance of a cartridge based assay for the detection of clinically significant HPV infection - lessons from VALGENT (Validation of HPV Genotyping Tests). J Clin Microbiol. 2016;54:2337–2347.
   PubMed Web of Science ®Google Scholar
• Heard I, Cuschieri K, Geraets DT, et al. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework. J Clin Virol. 2016;81:6–11.
   PubMed Web of Science ®Google Scholar
• Ostrbenk A, Xu L, Arbyn M, et al. Clinical and analytical evaluation of the Anyplex II HPV HR Detection assay within the VALGENT-3 framework. J Clin Microbiol. 2018;56:e01176–18.
   PubMed Web of Science ®Google Scholar
• Polman NJ, Ostrbenk A, Xu L, et al. Evaluation of the clinical performance of the HPV-Risk assay using the VALGENT-3 panel. J Clin Microbiol. 2017;55:3544–3551.
   PubMed Web of Science ®Google Scholar
• Viti J, Poljak M, Ostrbenk A, et al. Validation of EUROArray HPV test using the VALGENT framework. J Clin Virol. 2018;108:38–42.
   PubMed Web of Science ®Google Scholar
• Xu L, Ostrbenk A, Poljak M, et al. Assessment of the Roche Linear Array HPV genotyping test within the VALGENT framework. J Clin Virol. 2018;98:37–42.
   PubMed Web of Science ®Google Scholar
• Xu L, Padalko E, Ostrbenk A, et al. Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework. Int J Mol Sci. 2018;19.
   Web of Science ®Google Scholar
• Bonde J, Ejegod DM, Cuschieri K, et al. The Valgent4 protocol: robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. J Clin Virol. 2018;108:64–71.
   PubMed Web of Science ®Google Scholar
• Poljak M, Ostrbenk A, Seme K, et al. Comparison of clinical and analytical performance of the abbott realtime high risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol. 2011;49:1721–1729.
   PubMed Web of Science ®Google Scholar
• Meijer CJLM, Castle PE, Hesselink AT, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516–520.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Deeks JJ, Egger M, et al. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics. 2007;8:239–251.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Whiting P. metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J. 2009;9:211–229.
   Web of Science ®Google Scholar
• Deeks JJ, Bossuyt PM, Gatsonis C (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration. 2013.Available from: http://srdta.cochrane.org/.
   Google Scholar
• Takwoingi Y, Leeflang MM, Deeks JJ. Empirical evidence of the importance of comparative studies of diagnostic test accuracy. Ann Intern Med. 2013;158:544–554.
   PubMed Web of Science ®Google Scholar
• Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Verdoodt F, Snijders PJF, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15:172–183.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Martin-Hirsch P, Wentzensen N. Human papillomavirus-based triage of women showing a cervical cytology result of borderline or mild dyskaryosis. BJOG 2010;117:641–644.
   Google Scholar
• Del Mistro A, Adcock R, Carozzi F, et al. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. Int J Cancer. 2018;143:333–342.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst. 2015;107.
   Google Scholar